Brain Cancer Market Report 2026

The brain cancer market size has grown strongly in recent years. It will grow from $3.35 billion in 2025 to $3.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing brain cancer incidence, growing adoption of neuroimaging techniques, rising demand for chemotherapy and radiotherapy, expanding access to specialized cancer centers, increasing healthcare expenditure.

The brain cancer market size is expected to see strong growth in the next few years. It will grow to $4.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing demand for targeted therapies, rising adoption of immunotherapies, expanding use of minimally invasive neurosurgeries, increasing focus on early diagnosis, growing investment in oncology infrastructure. Major trends in the forecast period include advancement in AI-based diagnostic tools, development of personalized medicine solutions, innovation in immunotherapy combinations, progress in liquid biopsy technologies, and research and development in high-precision imaging systems.

The rising incidence of neurological tumors is expected to drive the expansion of the brain cancer sector in the coming years. Neurological tumors are abnormal, often malignant, growths within the brain or central nervous system that disrupt neurological function and require complex clinical management. The incidence of these tumors is increasing due to demographic factors such as population aging and growth, as older age is associated with a higher risk of developing brain cancers. The brain cancer sector addresses the prevalence of neurological tumors by providing expanded diagnostic, treatment, and care services to meet the clinical needs of the growing patient population. For example, in January 2025, the American Cancer Society, a US-based non-profit organization, reported that an estimated 14,040 new cases of brain tumors and other nervous system cancers are expected in males and 10,780 in females in 2025, with a total estimated death count of 18,330. Consequently, the rising incidence of neurological tumors is driving the growth of the brain cancer sector.

Leading companies in the brain cancer sector are concentrating on developing advanced diagnostic and imaging technologies, such as AI‑driven MRI segmentation platforms, to enhance clinical decision-making and treatment planning. AI‑driven MRI segmentation platforms are software solutions that leverage artificial intelligence to automatically identify and delineate anatomical structures or lesions on MRI scans, supporting faster and more consistent diagnosis and treatment planning. For example, in July 2025, Cortechs.ai, a US‑based medical imaging software company, introduced NeuroQuant Brain Tumor with upgraded AI-driven MRI segmentation models, providing automated volumetric quantification and metastasis/meningioma segmentation that enhances radiologist efficiency and diagnostic consistency compared with manual interpretation, along with cloud-based deployment and PACS integration for rapid scalability. By delivering objective segmentations and volumetric reports, this innovative technology improves the efficiency and standardization of radiologists, neurosurgeons, and neuro-oncologists while saving time and enhancing clinical consistency and diagnostic confidence. Clinicians can directly support better patient outcomes by monitoring tumour changes over time and gaining valuable insights into therapy response and disease progression.

In October 2024, Merck & Co. Inc., a US-based healthcare company, acquired Modifi Biosciences Inc. for around $1.3 billion. Through this acquisition, Merck strengthened its oncology pipeline by incorporating Modifi’s innovative cancer therapeutics aimed at glioblastoma and other hard-to-treat tumors, moving preclinical compounds closer to clinical development. Modifi Biosciences Inc. is a US-based biotechnology company focused on developing DNA repair-targeted cancer therapies, including treatments for gliomas and other brain tumors.

Major companies operating in the brain cancer market are Providence Health & Services, Ascension Health, Trinity Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, The Mount Sinai Hospital, The University of Texas MD Anderson Cancer Center, CommonSpirit Health, City of Hope National Medical Center, Stanford Health Care, Apollo Hospitals Enterprise Limited, Elekta AB, H. Lee Moffitt Cancer Center & Research Institute Inc., Roswell Park Comprehensive Cancer Center, Fred Hutchinson Cancer Center, Fortis Healthcare Limited, Dana-Farber Cancer Institute Inc., The Johns Hopkins Hospital, The Regents of the University of California.

North America was the largest region in the brain cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have affected the brain cancer market by increasing the cost of imported medical devices, imaging equipment, and chemotherapy drugs, causing delays in treatment adoption and procurement. high-impact segments include diagnostic imaging and surgical devices, particularly in regions like north america and europe that rely on imported advanced technologies. while costs have risen, tariffs have encouraged local manufacturing and innovation in medical equipment, potentially driving the development of more cost-efficient solutions.

Brain cancer is a condition marked by the uncontrolled proliferation of abnormal cells within the brain tissue. These tumors may be malignant, spreading quickly and disrupting normal brain function, or benign, growing slowly without spreading. The disease can lead to various neurological symptoms depending on the tumor’s size and location, often necessitating medical treatments such as surgery, radiation, or chemotherapy.

The main product types in brain cancer management include therapeutic treatments, diagnostic imaging, surgical devices, and supportive care products. Therapeutic treatments include chemotherapy, targeted therapy, and immunotherapy, designed to control tumor growth and improve outcomes. Surgical approaches include tumor resection, minimally invasive surgery, and stereotactic surgery. Diagnostic strategies include imaging, biopsy, molecular testing, and genetic testing. Supportive care services include rehabilitation, palliative care, counseling, and follow-up care, with key end users such as hospitals, specialty clinics, and research institutions.

The brain cancer market includes revenue earned by entities through diagnosis, surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, rehabilitation, palliative care, counseling, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.